



# Reproductive ageing—turning back the clock?

Yvonne O'Brien<sup>1,2,3</sup> · Mary B. Wingfield<sup>1,2,3</sup>

Received: 7 December 2017 / Accepted: 15 February 2018 / Published online: 2 March 2018  
© Royal Academy of Medicine in Ireland 2018

## Abstract

**Background** Unintended childlessness is a distressing, and often unintended, consequence of delayed childbearing and reproductive ageing. The average maternal age at first birth has risen steadily in many industrialised countries since the 1980s. There are many societal factors involved in the decision to postpone motherhood. As a result, many women are postponing having children until it is too late. In this review, we aim to summarise the reasons behind delayed childbearing, the impact of delayed childbearing and the scientific advances that seek to reverse reproductive ageing and ensure reproductive autonomy for women. **Methods** An extensive literature search of PubMed was conducted to include all published articles on delayed childbearing and the consequences of reproductive ageing. Secondary articles were identified from key paper reference listings. **Conclusion** If the current reproductive trends continue, many women will find themselves in the harrowing position of being unintentionally childless. In addition, many will inevitably turn to assisted reproductive technologies in an effort to protect and preserve their reproductive autonomy. However, it is not always possible to reverse the effects of reproductive ageing.

**Keywords** Assisted reproductive technology · Fertility · Oocyte vitrification · Ovarian reserve · Reproduction

## Trends in reproductive timing

Over the past four decades, the number of women postponing pregnancy has continued to increase, significantly impacting the age of first-time mothers. Mean maternal age at first birth rose by 1.5 years between 1980 and 1993 in EU countries [1], and a continued shift toward delayed childbearing is supported in other population studies [2–5]. Ireland is no exception to this trend. According to the HSE Perinatal Statistics report in 2013, the average age of women giving birth rose from 30.8 years in 2004 to 32.1 years in 2013. Births to primiparous women aged 40 years and older accounted for 1.8% of births in 2004 compared to 3.5% in 2013 [6].

The transition into parenthood is a major life event, and many prospective parents deliberate its timing carefully [7]. Maternal age at first birth often influences the total number of

births that a woman will have in her life and has far-reaching implications for society including size, composition and future growth of the population [8]. This phenomenon of delayed childbearing continues to expand, despite well-documented evidence of a decrease in fertility and fecundity with increasing age [9].

## Determinants of delayed childbearing

The trend of delayed childbearing and the consequential increase in unintended childlessness are multifaceted in origin. Level of education, parenthood “readiness”, prolonged adolescence and absence of a suitable partner have all been shown to be contributory factors [7, 10–14].

This trend is dominant among women with at least a high school education in the USA [3]. Findings from the National Childhood Development Study in the UK indicate that more intelligent women are more likely to remain childless by the end of their reproductive years. One-standard-deviation increase in childhood general intelligence decreases a women’s odds of parenthood by 21–25% [15]. From the Swedish population register, predictors of being childless were related to growing up in a large city, having well-educated parents, no siblings and not having moved from home at age 22. Principal

✉ Yvonne O’Brien  
yobrien@merriionfertility.ie

<sup>1</sup> Merrion Fertility Clinic, National Maternity Hospital, 60 Lower Mount Street, Dublin 2 D02 NH93, Ireland

<sup>2</sup> National Maternity Hospital, Holles Street, Dublin 2, Ireland

<sup>3</sup> School of Medicine, University College Dublin, Dublin 4, Ireland

reasons for not having children were not yet being prepared for parenthood, followed by not having met a suitable partner [2]. Relationship status and feeling “ready” were also dominant themes in qualitative work by Cooke that assessed determinants of delayed childbearing [10], supported in a meta-synthesis by the same group [16].

The impact of the media on reproductive choices and trends cannot be overstated. A study of women aged 15–49 years performed by Westoff and colleagues evaluated the number of children born in the preceding 5 years, and identified a consistent decrease that correlated with television exposure. The authors concluded that television exposes viewers to features of modern life that often are in competition with traditional attitudes toward marriage and the family and have the potential to influence reproductive behaviour [17]. Media, as a whole, is recognised to profoundly influence the definition of what is “normal” and “reasonable” behaviour in health-related issues [18]. Based on a qualitative, exploratory analysis of media representations of maternal age and older mothers in the UK, Mills proposes that media portrayals of older mothers are likely to have a positive impact on public perceptions of delayed childbearing. Three main themes emerged from their study: (1) delaying childbearing was often a conscious choice and allowed women to achieve other goals, (2) age was not a barrier to childbearing and (3) with advances in medical technology, reproductive problems could be addressed [4]. The positive sentiments of the media portrayal of older mothers could be interpreted as an endorsement of delayed childbearing and could well be contributing to the current trend.

Another powerful determinant of delayed childbearing is the belief that assisted reproductive technology (ART) can reverse the biological clock. The growing popularity and use of ART has given women the false impression that it is possible to manipulate the biological clock regardless of age [19]. Many women incorrectly believe that ART will be successful up until menopause [19–22].

## Impact of delayed childbearing

### Fertility

It is well-documented that fecundity and fertility decrease with advancing age. Epidemiological studies have demonstrated that fertility starts to decline at 30 years of age and is largely diminished by 40 years [23, 24]. Probability of pregnancy is twice as high for women aged 19–26 years compared to women aged 35–39 years [9]. Delayed childbearing until after 35 years of age has doubled the incidence of involuntary childlessness in the last two decades [25]. From a simulation model of reproduction, Leridon et al. report that 14% of women will remain childless if they delay starting to try to conceive until the age of 35 and 34.8% if they delay to age 40 [26].

Reasons for age-related fertility decline include reduced oocyte numbers and quality, reduced embryo quality and an increase in miscarriage rates due to aneuploidy. In a study by Rosen and colleagues, antral follicle counts as a marker of ovarian reserve were significantly lower in infertile women than in control women across age groups up to 40 years of age [27]. Reduction in oocyte quantity is also accompanied by a reduction in oocyte quality. Approximately 10–30% of fertilised human oocytes are thought to be aneuploid, with the majority being either trisomic or monosomic. Aneuploidy is the most commonly identified chromosome abnormality in humans, occurring in at least 5% of all clinically recognised pregnancies [28]. Approximately one-third of all miscarriages are aneuploid, making it the leading known cause of pregnancy loss. Of conceptions that survive to term, aneuploidy is the primary genetic cause of intellectual disability [28]. Age is the strongest predictor of numerical chromosomal anomalies [29]. Approximately 2% of clinically recognised pregnancies of women under the age of 25 is affected by trisomy, compared to 35% for women over the age of 40 [28]. Franasiak et al. reviewed 15,169 consecutive trophoblast biopsies screened for chromosomal abnormalities and showed that aneuploidy increased in a predictable fashion after 26 years of age [30].

The origin of aneuploidy has inspired much interest and research over the past two decades. Most trisomies occur as a result of errors of the first meiotic division of the oocyte, which is only completed at the time of ovulation [28]. The link between increasing maternal age and risk of aneuploidy has been well-documented historically, and the association between increasing maternal age and Down syndrome was recognised as early as 1933 [31]. The ageing process also correlates with an increase in mitochondrial dysfunction, impacting on oocyte quality; however, further research is needed in this area [32]. Similarly, the impact of increasing maternal age on diminished uterine receptivity has not yet been fully elucidated [33].

Delayed childbearing is one of the main contributory factors to the increasing use of ART in many countries [34]. Despite advances in the field, modern technology remains unable to completely reverse the biological clock. Success of IVF and embryo transfer declines with each year and is particularly low in women over 40 years of age [35–37]. Therefore, the application of ART as a solution to age-related fertility decline will not compensate for all births lost as a result of this phenomenon [38].

### Foetal outcomes

The impact of delayed childbearing and reproductive ageing on foetal outcomes is significant at every gestational age and outcome studied. Anderson et al. demonstrated that the risk of a spontaneous abortion was 8.9% in women aged 20–24 years

and 74.7% in those aged 45 years or more [39]. This study also demonstrated that the effect of maternal age on spontaneous abortion risk was independent of parity and reproductive history. Advancing maternal age is further linked to an increased risk of ectopic pregnancy [40, 41] and to increased rates of preterm delivery, even when studies were adjusted for the coexistence of other obstetrical complications and preexisting maternal diseases already associated with older age groups [42–45].

When adjusting for confounding factors, intrauterine growth restriction (IUGR) is seen in higher proportions in older mothers than younger mothers [44, 46]. Furthermore, there is an increased risk of intrauterine foetal death with advancing maternal age [47]. A population-based study of 334,339 infants demonstrated that maternal age greater than 35 years was associated with an increased incidence of cerebral palsy [48].

As older prospective mothers turn to ART to avoid unintended childlessness, cumulative negative foetal impacts are anticipated. ART (IVF/ICSI) is associated with a higher incidence of prematurity, IUGR, foetal malformations and genomic-imprinting diseases [49–53].

### Maternal outcomes

The significant risks to the health and life of the mother that result from delayed childbearing have also been well-documented [54]. While older women are expected to have naturally developed more chronic illnesses by the time of pregnancy, this still does not account for all the negative, adverse events that are linked to increasing maternal age [55]. The increased risk of maternal mortality is most notable after 35 years of age [56]. Maternal mortality most often occurs as a result of cardiovascular disease, diabetes, placental abruption and complications arising from operative deliveries [57]. There is also a significant maternal morbidity burden associated with advancing maternal age, with women aged 35 years or older displaying increased risk of gestational diabetes and pregnancy-associated hypertensive diseases [58, 59].

### Scientific advances with the aim of circumventing unintended childlessness while protecting genetic autonomy due to delayed childbearing

In view of this unprecedented increase in delayed childbearing and its consequential unintended effects, several important advances now offer women an opportunity to avoid this potentially devastating position. Ovarian reserve testing and the advent of oocyte vitrification (egg freezing) for social reasons may now allow women to postpone childbearing without risking the situation of unintended childlessness or having to resort to the route of oocyte donation in an attempt to become a parent. Adjuncts to ART may also give some hope to prospective

parents in the future. These include the further development and improvement of preimplantation genetic screening (PGS) and the possible identification of novel non-invasive biomarkers of egg quality. Interestingly, our recent study showed that Irish women are very open to the use of modern technologies in an attempt to avoid unintended childlessness [60].

### Oocyte donation

Oocyte donation has become a well-established practice in reproductive medicine and has been used to treat women with premature ovarian failure and those women presenting with advanced reproductive age [61]. This form of ART has continued to result in excellent success rates [62]. This is essentially as a result of the decrease in reduced oocyte quality owing to a very young, healthy donor population [61]. Despite excellent success rates, the technique is viewed by some as ethically contentious [63]. There is concern relating to the recruitment of healthy young women for donor programmes, often enticed by financial reward [61]. Furthermore, there is a lack of longitudinal studies documenting the long-term effects of treatment on donors, recipients, children born or the families created [61].

### Ovarian reserve testing

Ovarian reserve refers to the size of the ovarian follicular pool and is determined by the net result of the original size of the primordial follicle pool, the natural rate of atretic loss and the influence of any insult or injury to the ovary that may accelerate follicle depletion [64]. It is documented that up to 10% of women in their mid-30s are involuntarily sterile due to diminished ovarian reserve [65]. Ovarian reserve testing refers to efforts to measure the reproductive potential of an individual as a function of the quantity of remaining oocytes [66]. A recent study in the Merrion Fertility Clinic sought to evaluate risk factors for women with low anti-Müllerian hormone (AMH) levels indicating low ovarian reserve and demonstrated that the presence of clinical risk factors will only identify half of women at risk of low ovarian reserve [67].

AMH levels are currently the best available measure of ovarian reserve [66]. Granulosa cells of the preantral and small antral follicles are responsible for producing AMH [68]. Serum AMH levels have shown great sensitivity to ovarian ageing and significant correlation with antral follicle count [69]. Ovarian reserve can have a significant effect on future reproductive potential and on success rates with assisted reproduction [70, 71]. However, other studies contradict the efficacy of AMH testing in predicting immediate natural conception [72]. Serum AMH has been employed as a useful predictor of ovarian response to controlled ovarian stimulation (COS) [73], and as a marker of oocyte and embryo quality during COS [74, 75].

At present, serum AMH testing is not recommended as a population-based screening test for young women, although this prospect is increasingly discussed in medical circles [64]. The ethical and clinical impacts of AMH testing and ovarian reserve screening are complex and multifaceted and have not been fully elucidated. Individualised ovarian reserve screen may have the potential to impact a woman's reproductive behaviour, rather than generic, non-personalised age-related fertility advice. Some studies have shown that, if empowered with their individual ovarian reserve status, the decisions women make regarding further education and career may be different [76, 77]. Knowledge of a low ovarian reserve status may help women choose to prioritise motherhood earlier than planned, or to consider oocyte vitrification. While there are potential psychological benefits to be gained by ovarian reserve testing when a result reflects adequate ovarian reserve, the unexpected diagnosis of a critical ovarian reserve level could be devastating. A recent qualitative study in the Merrion Fertility Clinic explored the psychological impact of AMH testing and demonstrated the significant negative impact of communicating a low AMH result to women undergoing fertility investigations.

### Oocyte Vitrification

Oocyte vitrification or “social egg freezing” to combat one's own reproductive ageing is a relatively new practice. However, it has been used for over a decade as an efficient, effective technique in oocyte donation programmes [78–80]. A large retrospective cohort study of children born after use of vitrified or fresh oocytes concluded that the process of vitrification had no clinically relevant adverse effects on obstetric and perinatal outcomes after adjusting for potential confounders [81]. As a result of increasing evidence for the safety of the procedure, it has recently been reclassified as non-experimental by the American Society of Reproductive Medicine (ASRM) and the European Society for Human Reproduction and Embryology (ESHRE) [82, 83], and is increasingly being offered to women in an attempt to avoid unintended childlessness without affecting genetic autonomy.

Vitrification or cryopreservation refers to the cooling of cells and tissues to sub-zero temperatures to stop all biologic activity, so that they can be preserved for future use. Initial success was limited by cellular damage, ice crystal formation or excessive dehydration. The use of cryoprotectants subsequently improved cryopreservation techniques, and the first human birth from a frozen oocyte was reported in 1986 [84]. The original slow freeze technique has now been largely replaced by vitrification, which uses high concentrations of cryoprotectants and rapid cooling to avoid ice crystal formation. The human metaphase II oocyte is an extraordinary but very fragile cell, owing to its large water content, larger size and chromosomal rearrangement. Susceptibility to spindle

apparatus damage by ice formation may be dependent on patient age [85], as 80% of oocytes are aneuploid at age 40 years [86].

A retrospective multicentre study of 1468 women undergoing oocyte vitrification for fertility preservation demonstrated that at least 8–10 metaphase II oocytes were necessary to achieve a reasonable chance of pregnancy. The authors concluded that optimal oocyte number should be individualised when the woman is aged 36 years or older. Rates of oocyte survival, clinical pregnancy, ongoing pregnancy and livebirth were all significantly higher in the under 35-year age group, i.e. the age at time of oocyte vitrification [87]. However, the demographic profile of women presenting for fertility preservation using oocyte vitrification shows that they are doing so at a suboptimal age and consulting too late for treatment [87]. It is important, when counselling the cohort of women that attend for fertility preservation, to use data applicable to them and to avoid false reassurances by quoting survival and pregnancy rates from donor oocytes from very young women [88, 89].

### Adjuncts to ART

With an ever-increasing need for ART, the focus on success rates has never been more to the fore. To improve ART outcomes for women who delay childbearing, PGS and biomarkers of oocyte and embryo quality may be of benefit.

### Preimplantation genetic screening

PGS refers to the selection of euploid embryos for transfer in an effort to increase the chances of a healthy pregnancy. This technique was proposed as far back as the early 1990s [90]. The main indications for this technique include advanced maternal age, repeated implantation failure, recurrent miscarriage and severe male factor infertility, as these specific patient groups have a higher chance of producing aneuploid embryos.

There is extensive international debate regarding the value and place of PGS. A meta-analysis by Chen et al. concluded that PGS cycles, when compared to those using only morphological methods of embryo assessment, improved rates of implantation, clinical pregnancy, ongoing pregnancy and live birth while reducing miscarriage rates [91]. However, these findings have not been reproduced in prospective randomised controlled trials [92–94]. Ongoing developments and technical improvements in PGS (which include progression from fluorescence in situ hybridization (FISH) to current use of massive parallel sequencing) [90] may affect these conclusions.

While PGS has been proposed for women of advanced maternal age, there are a number of studies demonstrating that older women do not benefit, and that PGS may actually reduce pregnancy rates in this cohort [92]. This may be explained by false-positive aneuploid detection in trophoblast biopsies,

due to mosaicism in blastocyst-stage embryos. Although such embryos are typically discarded, studies have shown that mosaic embryos are in fact still capable of producing healthy babies [95]. The widespread, clinical application of PGS for this aged patient cohort in particular has become a very contentious issue in IVF. Without substantial evidence proving the effectiveness and safety of the procedure, the routine use of PGS should not be advocated.

### Potential biomarkers of oocyte quality and early embryonic development

The discovery of an accurate, non-invasive and cost-effective predictive test of the development potential of an oocyte or embryo is an important goal of much ongoing research worldwide. However, this concept of predetermining an oocytes' potential remains a major obstacle [96]. The potential implications of such a discovery could have major impacts not only on IVF treatment, but also on oocyte vitrification for the purposes of fertility preservation. We know that only a small number of the oocytes retrieved in an IVF cycle have the potential to develop into a viable embryo resulting in a live birth [97]. As a result, in some cases, multiple embryos are transferred per treatment cycle with a view to increasing pregnancy rates. Increasing pregnancy rates then occur at the expense of increased risk of complications for both mother and offspring [98]. A predictive test of developmental potential to aid in oocyte selection could therefore have a major impact on the practice of embryo transfer, embryo storage and oocyte vitrification. In contrast to the current policy of vitrifying a minimum of 8–10 metaphase II oocytes to ensure a reasonable chance of achieving pregnancy [87], it may be possible to provide a more individualised approach in counselling women about the need for further stimulation cycles to achieve the optimal number of oocytes for them.

### Conclusion

If current societal reproductive trends continue, many women will find themselves in the harrowing position of being unintentionally childless. Many will inevitably turn to ART in an effort to protect and preserve their reproductive autonomy. Technological advances, such as ovarian reserve testing, oocyte vitrification, PGS and the advent of biomarkers of oocyte and embryo quality, offer increasing hope to this group. However, it is clear that, even with this technology, the adverse effects of reproductive ageing on the female biological clock are not reversible. Compared to natural conception at an early age (< 30 years), technology is, at best, a second-rate option. It is therefore incumbent upon health agencies and healthcare professionals to provide the public with appropriate education and information and to be more proactive in

enabling young women to access these services if required. On a broader level, society must also address some of the issues that prevent young people from pursuing parenthood at a time when they have a reasonable chance of fulfilling their intentions of having a family.

### Compliance with ethical standards

**Ethical approval** This article does not contain any studies with human participants performed by any of the authors.

**Conflict of interest statement** The authors declare that they have no conflict of interests.

### References

- Breart G (1997) Delayed childbearing. *Eur J Obstet Gynecol Reprod Biol* 75(1):71–73
- Waldenström U (2016) Postponing parenthood to advanced age. *Ups J Med Sci* 9734(September):1–9
- Heck KE, Schoendorf KC, Ventura SJ, Kiely JL (1997) Delayed childbearing by education level in the United States, 1969–1994. *Matern Child Health J* 1(2):81–88
- Mills TA, Lavender R, Lavender T (2015) “Forty is the new twenty”: an analysis of British media portrayals of older mothers. *Sex Reprod Healthc* 6(2):88–94
- Ledger WL (2009) Demographics of infertility. *Reprod Biomed Online* 18(Suppl 2):11–14
- HSE (2014) 2013 Perinatal Statistics Report. [http://www.hse.ie/eng/services/publications/Perinatal\\_Statistics\\_Report\\_2013.pdf](http://www.hse.ie/eng/services/publications/Perinatal_Statistics_Report_2013.pdf)
- Schytt E, Nilsen ABV, Bernhardt E (2014) Still childless at the age of 28 to 40 years: a cross-sectional study of Swedish women's and men's reproductive intentions. *Sex Reprod Healthc* 5(1):23–29
- Matthews TJ, Hamilton BE (2009) Delayed childbearing: more women are having their first child later in life. *NCHS Data Brief* 21:1–8
- Dunson DB, Colombo B, Baird DD (2002) Changes with age in the level and duration of fertility in the menstrual cycle. *Hum Reprod* 17(5):1399–1403
- Cooke A, Mills TA, Lavender T (2012) Advanced maternal age: delayed childbearing is rarely a conscious choice. A qualitative study of women's views and experiences. *Int J Nurs Stud* 49(1):30–39
- Rijken AJ, Liefbroer AC (2009) Influences of the family of origin on the timing and quantum of fertility in the Netherlands. *Popul Stud (NY)* 63(1):71–85
- Mills M, Rindfuss RR, McDonald P, te Velde E, on behalf of the ESHRE Reproduction and Society Task Force (2011) Why do people postpone parenthood? Reasons and social policy incentives. *Hum Reprod Update* 17(6):848–860
- Tough S, Tofflemire K, Benzies K, Fraser-Lee N, Newburn-Cook C (2007) Factors influencing childbearing decisions and knowledge of perinatal risks among Canadian men and women. *Matern Child Health J* 11(2):189–198
- Thompson R, Lee C (2011) Sooner or later? Young Australian men's perspectives on timing of parenthood. *J Health Psychol* 16(5):807–818
- Kanazawa S (2014) Intelligence and childlessness. *Soc Sci Res* 48:157–170
- Cooke A, Mills TA, Lavender T (2010) “Informed and uninformed decision making”—women's reasoning, experiences and

- perceptions with regard to advanced maternal age and delayed childbearing: a meta-synthesis. *Int J Nurs Stud* 47(10):1317–1329
17. Westoff CF, Koffman DA (2011) The association of television and radio with reproductive behavior. *Popul Dev Rev* 37(4):749–759
  18. Dutta-Bergman MJ (2004) Primary sources of health information: comparisons in the domain of health attitudes, health cognitions, and health behaviors. *Health Commun* 16(3):273–288
  19. Wyndham N, Marin Figueira PG, Patrizio P (2012) A persistent misperception: assisted reproductive technology can reverse the “aged biological clock”. *Fertil Steril* 97(5):1044–1047
  20. Bromer JG, Patrizio P (2008) Preservation and postponement of female fertility. *Placenta* 29(SUPPL.2):200–205
  21. Benzie K, Tough S, Tofflemire K, Frick C, Faber A, Newburn-Cook C (2006) Factors influencing women’s decisions about timing of motherhood. *J Obstet Gynecol Neonatal Nurs* 35(5):625–633
  22. Maheshwari A, Porter M, Shetty A, Bhattacharya S (2008) Women’s awareness and perceptions of delay in childbearing. *Fertil Steril* 90(4):1036–1042
  23. van Noord-Zaadstra BM, Looman CW, Alsbach H, Habbema JD, te Velde ER, Karbaat J (1991) Delaying childbearing: effect of age on fecundity and outcome of pregnancy. *BMJ* 302(6789):1361–1365
  24. Gosden R (1995) Delayed childbearing. *BMJ* 311:1585–1586
  25. Te Velde E, Habbema D, Leridon H et al (2012) The effect of postponement of first motherhood on permanent involuntary childlessness and total fertility rate in six European countries since the 1970s. *Hum Reprod* 27(4):1179–1183
  26. Leridon H, Slama R (2008) The impact of a decline in fecundity and of pregnancy postponement on final number of children and demand for assisted reproduction technology. *Hum Reprod* 23(6):1312–1319
  27. Rosen MP, Johnstone E, Addauan-Andersen C, Cedars MI (2011) A lower antral follicle count is associated with infertility. *Fertil Steril* 95(6):1950–1954.e1
  28. Hassold T, Hunt P (2001) To err (meiotically) is human: the genesis of human aneuploidy. *Nat Rev Genet* 2(April):280–291
  29. Nicolaides KH (2005) First-trimester screening for chromosomal abnormalities. *Semin Perinatol* 29(4):190–194
  30. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, Scott RT Jr (2014) The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. *Fertil Steril* 101(3):656–663
  31. Penrose L (1933) The relative effects of paternal and maternal age in mongolism. *J Genet* 27:219–224
  32. Bentov Y, Yavorska T, Esfandiari N, Jurisicova A, Casper RF et al (2011) The contribution of mitochondrial function to reproductive aging. *J Assist Reprod Genet* 28:773–783
  33. Balasch JGE (2012) Delayed childbearing: effects on fertility and the outcome of pregnancy. *Curr Opin Obs Gynecol* 75(1):187–193
  34. Broekmans FJ, Knauff EAH, Velde ER et al (2007) Female reproductive ageing: current knowledge and future trends. *Trends Endocrinol Metab* 18(2):58–65
  35. O’Brien YM, Ryan M, Martyn F et al (2017) A retrospective study of the effect of increasing age on success rates of assisted reproductive technology. *Int J Gynecol Obstet* 138(1):42–46
  36. Balasch J, Gratacós E (2011) Delayed childbearing: effects on fertility and the outcome of pregnancy. *Fetal Diagn Ther* 29(4):263–273
  37. Tsafirir A, Simon A, Revel A, Reubinoff B, Lewin A, Laufer N (2007) Retrospective analysis of 1217 IVF cycles in women aged 40 years and older. *Reprod BioMed Online* 14(3):348–355
  38. Leridon H (2004) Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment. *Hum Reprod* 19(7):1548–1553
  39. Nybo Andersen AM, Wohlfahrt J, Christens P et al (2000) Maternal age and fetal loss: population based register linkage study. *BMJ* 320(7251):1708–1712
  40. Bouyer J (2003) Epidemiology of ectopic pregnancy: incidence, risk factors and outcomes. *J Gynecol Obstet Biol Reprod (Paris)* 32(7 Suppl):S8–17
  41. Khoshnood B, Bouvier-Colle M-H, Leridon H et al (2008) Impact of advanced maternal age on fecundity and women’s and children’s health. *Impact l’age Matern. Elev. sur la Fertil. la sante la mere la sante l’enfant* 37(8):733–747
  42. Foix-L’Helias L, Blondel B (2000) Changes in risk factors of preterm delivery in France between 1981 and 1995. *Paediatr Perinat Epidemiol* 14(4):314–323
  43. Ogawa K, Urayama KY, Tanigaki S et al. (2017) *BMC pregnancy childbirth* 10. 17(1):349
  44. Joseph KS, Allen AC, Dodds L, Turner LA, Scott H, Liston R (2005) The perinatal effects of delayed childbearing. *Obstet Gynecol* 105(6):1410–1418
  45. Cnattingius S, Forman MR, Berendes HW II (1992) Delayed childbearing and risk of adverse perinatal outcome. *J Am Med Assoc* 268(7):886–890
  46. Odibo AO, Nelson D, Stamilio DM et al. (2006) Advanced maternal age is an independent risk factor for intrauterine growth restriction. *Am J Perinatol* 1(212):325–8
  47. Huang L, Sauve R, Birkett N, Fergusson D, van Walraven C (2008) Maternal age and risk of stillbirth: a systematic review. *Can Med Assoc J* 178(2):165–172
  48. Wu YW, Croen LA, Shah SJ, Newman TB, Najjar DV (2006) Cerebral palsy in a term population: risk factors and neuroimaging findings. *Pediatrics* 118(2):690–697
  49. Grady R, Alavi N, Vale R, Khandwala M, McDonald SD (2012) Elective single embryo transfer and perinatal outcomes: a systematic review and meta-analysis. *Fertil Steril* 97(2):324–331
  50. Kalra SK, Ratcliffe SJ, Coutifaris C, Molinaro T, Barnhart KT (2011) Ovarian stimulation and low birth weight in infants conceived through in vitro fertilization. *Obstet Gynecol* 118(4):863–871
  51. Sagot P, Bechoua S, Ferdynus C, Facy A, Flamm X, Gouyon JB, Jimenez C (2012) Similarly increased congenital anomaly rates after intrauterine insemination and IVF technologies: a retrospective cohort study. *Hum Reprod* 27(3):902–909
  52. Gosden R, Trasler J, Lucifero D, Faddy M (2003) Rare congenital disorders, imprinted genes, and assisted reproductive technology. *Lancet* 361(9373):1975–1977
  53. Rossignol S, Steunou V, Chalas C, Kerjean A, Rigolet M, Viegas-Pequignot E, Jouannet P, le Bouc Y, Gicquel C (2006) The epigenetic imprinting defect of patients with Beckwith-Wiedemann syndrome born after assisted reproductive technology is not restricted to the 11p15 region. *J Med Genet* 43(12):902–907
  54. Usta I, Nassar A (2008) Advanced maternal age. Part I: obstetric complications. *Am J Perinatol* 25(8):521–534
  55. Sauer MV (2015) Reproduction at an advanced maternal age and maternal health. *Fertil Steril* 103:1136–1143
  56. Wildman K, Bouvier-Colle M-H, MOMS Group (2004) Maternal mortality as an indicator of obstetric care in Europe. *BJOG* 111(2):164–169
  57. Jacobsson B, Ladfors L, Milsom I (2004) Advanced maternal age and adverse perinatal outcome. *Obstet Gynecol* 104(4):727–733
  58. Weerasekera DS, Udugama SG (2003) Pregnancy at 40 and over: a case-control study in a developing country. *J Obstet Gynaecol (Lahore)* 23:625–627
  59. Ziadeh SM, SM Z (2002) Maternal and perinatal outcome in nulliparous women aged 35 and older. *Gynecol Obstet Investig* 54(1):6–10
  60. O’Brien Y, Martyn F, Glover LE et al (2014) What women want? A scoping survey on women’s knowledge, attitudes and behaviours

- towards ovarian reserve testing and egg freezing. *Eur J Obstet Gynecol Reprod Biol* 217:71–76
61. Sauer MV, Kavac SM (2006) Oocyte and embryo donation: reviewing two decades of innovation and controversy. *Reprod BioMed Online* 12(2):153–162
  62. Cobo A, Remohi J, Chang C-C, Nagy ZP (2011) Oocyte cryopreservation for donor egg banking. *Reprod BioMed Online* 23:341–346
  63. Levine AD (2011) The oversight and practice of oocyte donation in the United States, United Kingdom and Canada. *HEC Forum* 23(1):15–30
  64. Tremellen K, Savulescu J (2014) Ovarian reserve screening: a scientific and ethical analysis. *Hum Reprod* 29(12):2606–2614
  65. te Velde ER, Pearson P (2002) The variability of female reproductive aging. *Hum Reprod Update* 8(2):141–154
  66. Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM (2014) Anti Mullerian hormone: ovarian reserve testing and its potential clinical implications. *Hum Reprod Update* 20(5):688–701
  67. Martyn F, O'Brien YM, Wingfield M (2017) Review of clinical indicators, including serum anti-Müllerian hormone levels, for identification of women who should consider egg freezing. *Int J Gynaecol Obstet* 138(1):37–41
  68. Vigier B, Picard JY, Tran D et al (1984) Production of anti-Müllerian hormone: another homology between sertoli and granulosa cells. *Endocrinology* 114(4):1315–1320
  69. De Vet A, Laven JSE, De Jong FH et al (2002) Anti-Mullerian hormone serum levels: a putative marker for ovarian aging. *Fertil Steril* 77(2):357–362
  70. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman SBD et al (2013) Antimüllerian hormone as a predictor of natural fecundability in women aged 30–42 years. *Obstet Gynaecol* 117(4):1–11
  71. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJC, Mol BWJ, Broekmans FJM, on behalf of the IMPORT study group, Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Anderson RA, Ashrafi M, Bancsi L, Caroppo LE, Copperman A, Ebner T, Eldar Geva M, Erdem M, Greenblatt EM, Jayaprakasan K, Fenning R, Klinkert ER, Kwee J, Lambalk CB, la Marca A, McIlveen M, Merce LT, Muttukrishna S, Nelson SM, Ng HY, Popovic-Todorovic B, Smeenk JMJ, Tomas C, van der Linden PJQ, van Rooij IA, Vladimirov IK, Bossuyt PB, Eijkemans MJC, Mol BW, Frank B (2013) Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. *Hum Reprod Update* 19(1):26–36
  72. Hagen CP, Vestergaard S, Juul A et al (2012) Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. *Fertil Steril* 98(6):1602–8.e2
  73. Seifer DB, MacLaughlin DT, Christian BP et al (2002) Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. *Fertil Steril* 77(3):468–471
  74. Seifer DB, MacLaughlin DT (2007) Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. *Fertil Steril* 88(3):539–546
  75. Silberstein T, MacLaughlin DT, Shai I et al (2006) Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. *Hum Reprod* 21(1):159–163
  76. Bavan B, Porzig E, Baker VL (2011) An assessment of female university students' attitudes toward screening technologies for ovarian reserve. *Fertil Steril* 96(5):1195–1199
  77. Aguinaldo ET, Morgan DC, Julliard K (2014) What would you do if you knew? *Obstet Gynecol* 123:187S
  78. Cobo A, Diaz C (2011) Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. *Fertil Steril* 96(2):277–285
  79. Cobo A, Meseguer M, Remohi J et al (2010) Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. *Hum Reprod* 25(9):2239–2246
  80. Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, Remohi J, Ragni G, Ubaldi FM (2012) Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. *Hum Reprod* 27(6):1606–1612
  81. Cobo A, Serra V, Garrido N, Olmo I, Pellicer A, Remohi J (2014) Obstetric and perinatal outcome of babies born from vitrified oocytes. *Fertil Steril* 102(4):1006–1015.e4
  82. Dondorp W, De Wert G, Pennings G et al (2012) Oocyte cryopreservation for age-related fertility loss. *Hum Reprod* 27(5):1231–1237
  83. ASRM (2013) Mature oocyte cryopreservation: a guideline. *Fertil Steril* 99(1):37–43
  84. Chen C (1986) Pregnancy after human oocyte cryopreservation. *Lancet* 1986 327(8486):884–886
  85. Bromfield JJ, Coticchio G, Hutt K, Sciajno R, Borini A, Albertini DF (2009) Meiotic spindle dynamics in human oocytes following slow-cooling cryopreservation. *Hum Reprod* 24(9):2114–2123
  86. Geraedts J, Montag M, Magli MC et al (2011) Polar body array CGH for prediction of the status of the corresponding oocyte. Part I: clinical results. *Hum Reprod* 26(11):3181–3185
  87. Cobo A, Garcia-Velasco JA, Coello A, Domingo J, Pellicer A, Remohi J (2016) Oocyte vitrification as an efficient option for elective fertility preservation. *Fertil Steril* 105(3):755–764.e8
  88. Nagy ZP, Chang CC, Shapiro DB, Bernal DP, Elsner CW, Mitchell-Leef D, Toledo AA, Kort HI (2009) Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. *Fertil Steril* 92(2):520–526
  89. García JI, Noriega-Portella L, Noriega-Hoces L (2011) Efficacy of oocyte vitrification combined with blastocyst stage transfer in an egg donation program. *Hum Reprod* 26(4):782–790
  90. Sermon K, Capalbo A, Cohen J et al (2016) The why, the how and the when of PGS 2.0: current practices and expert opinions of fertility specialists, molecular biologists, and embryologists. *Mol Hum Reprod* 22(8):545–557
  91. Chen M, Wei S, Hu J, Quan S (2015) Can comprehensive chromosome screening technology improve IVF/ICSI outcomes? A meta-analysis. *PLoS One* 10(10):1–21
  92. Mastenbroek S, Twisk M, van der Veen F, Repping S (2011) Preimplantation genetic screening: a systematic review and meta-analysis of RCTs. *Hum Reprod Update* 17(4):454–466
  93. Gleicher N, Kushnir VA, Barad DH (2014) Preimplantation genetic screening (PGS) still in search of a clinical application: a systematic review. *Reprod Biol Endocrinol* 12:22
  94. Lee E, Illingworth P, Wilton L, Chambers GM (2015) The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. *Hum Reprod* 30(2):473–483
  95. Greco E, Minasi MGFF (2015) Healthy babies after intrauterine transfer of mosaic aneuploid blastocysts. *N Engl J Med* 373:2089–2090
  96. O'Shea LC, Mehta J, Lonergan P et al (2012) Developmental competence in oocytes and cumulus cells: candidate genes and networks. *Syst Biol Reprod Med* 58(2):88–101
  97. Kovalevsky G, Patrizio P (2005) High rates of embryo wastage with use of assisted reproductive technology: a look at the trends between 1995 and 2001 in the United States. *Fertil Steril* 84(2):325–330
  98. Black M, Bhattacharya S (2010) Epidemiology of multiple pregnancy and the effect of assisted conception. *Semin Fetal Neonatal Med* 15(6):309–312